Filing Flows › Agios Pharmaceuticals (AGIO) › Q1 2026
Agios Pharmaceuticals (AGIO) Q1 2026 earnings results (first quarter 2026)
10-Q filed Apr 29, 2026
Agios Pharmaceuticals (AGIO) reported revenue of $20.7M for the first quarter 2026 (Q1 2026), +138% from a year earlier and +4% from the quarter before. Operating margin was -530.3%, net loss $99.1M (477.7% of revenue).
Agios Pharmaceuticals, Q1 2026: revenue $20.7M (+138% year over year), operating margin -530.3%, net loss $99.1M, operating cash flow −$119M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.7M | +4% | +138% |
| Operating profit | −$110M | — | — |
| Net earnings | −$99.1M | — | — |
| Operating cash flow | −$119M | — | — |
What changed
Revenue was $20.7M in Q1 2026, up 138% year over year and up 4% from the previous quarter.
Operating costs exceeded revenue by $110.0M, an operating margin of -530.3%. Total costs grew 13% against revenue growth of 138%. The fastest-growing cost line was Cost of revenue (+22%). The quarter ended with a net loss of $99.1M, narrower than the previous quarter's $108.0M loss.
Operating cash flow was −$118.9M. Non-cash charges added back $15.5M of share-based compensation. Working capital and other items used $35.4M. Capital expenditures of $769K exceeded it, leaving free cash flow of −$119.7M.
Questions
What was Agios Pharmaceuticals' revenue in the first quarter 2026?
Agios Pharmaceuticals (AGIO) reported revenue of $20.7M for the first quarter 2026 (Q1 2026), +138% from a year earlier and +4% from the quarter before.
Was Agios Pharmaceuticals profitable in the first quarter 2026?
Operating loss was $110M (-530.3% of revenue) and net loss $99.1M.